Fig. 3

OA-RD17 significantly decreased inflammation and promoted epidermal regeneration in diabetic patient ex vivo skin wounds. A Illustration of diabetic patient ex vivo skin wound model. B Representative images of H&E staining of diabetic patient ex vivo skin wound tissues on days 3 and 7. Yellow dotted lines represent areas of neoepithelium; NE: neoplastic epithelium; scale bar 200 μm. C Thickness variations in neodermis in wound tissue on days 3 and 7 of OA-RD17 treatment. D Epidermal migration length variation in neodermis in wound tissue on days 3 and 7 of OA-RD17 treatment. E Representative images of immunohistochemical staining for epidermal Ki67 expression after one week of OA-RD17 treatment; positive staining is indicated by red arrows, scale bar 50 μm. F Quantification of positive-staining intensity of Ki67 expression in epidermis. G Representative images of immunohistochemical staining for inflammatory factors IL-6, TNF-α, and IL-1β in wound area on day 7 of OA-RD17 treatment; positive staining is indicated by red arrows, scale bar 50 μm. H-J Quantification of intensity of IL-6, TNF-α, and IL-1β expression in wound area. All data are expressed as mean ± SEM from three independent experiments performed in triplicate. *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001 indicate statistically significant difference compared to vehicle